Efficacy of Icotinib, an EGFR Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer Patients with Exon 19 Deletion and Exon 21 L858R: A Retrospective Analysis in China
Conclusion: These results suggest thatEGFR 19-Del confers superior PFS and response to the icotinib treatment compared to 21-L858R.Pharmacology
Source: Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | China Health | Drugs & Pharmacology | Lung Cancer | Non-Small Cell Lung Cancer | Smokers | Study